Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma

• Published in: Journal of thoracic oncology 2012-04, Vol.7 (4), p.737-743
• Main Authors: Lang-Lazdunski, Loïc, Bille, Andrea, Lal, Rohit, Cane, Paul, McLean, Emma, Landau, David, Steele, Jeremy, Spicer, James
• Format: Article
• Language: English
• Subjects: Aged; Combined Modality Therapy; Extrapleural pneumonectomy; Female; Humans; Male; Malignant pleural mesothelioma; Mesothelioma - mortality; Mesothelioma - pathology; Mesothelioma - therapy; Middle Aged; Neoplasm Staging; Pleural Neoplasms - mortality; Pleural Neoplasms - pathology; Pleural Neoplasms - therapy; Pleurectomy; Pneumonectomy - methods; Prospective Studies
• ISSN: 1556-0864; 1556-1380
• DOI: 10.1097/JTO.0b013e31824ab6c5

To compare the outcomes of two different multimodality regimens involving neoadjuvant chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant radiotherapy versus pleurectomy/decortication (P/D), hyperthermic pleural lavage with povidone-iodine, and adjuvant chemotherapy in patients with malignant pleural mesothelioma. Nonrandomized prospective study of patients treated by multimodality therapy and operated on between January 2004 and June 2011. Second-line treatments were administered when appropriate. Survival and prognostic factors were analyzed by the Kaplan Meier method, log rank test, and Cox regression analysis. Twenty-five consecutive patients received neoadjuvant chemotherapy, 22 underwent EPP, and 17 received adjuvant radiotherapy. Over the same period, 54 consecutive patients underwent P/D and hyperthermic pleural lavage and received prophylactic radiotherapy and adjuvant chemotherapy. The 30-day mortality rate was 4.5%in the EPP group and nil in the P/D group. Fifteen patients (68%) in the EPP group and 15 (27.7%) in the P/D group experienced complications. There were no differences between the EPP and P/D groups for age, sex, histology, pathologic stage, and nodal status. Trimodality therapy was completed by 68%of the patients in the EPP group and 100%in the P/D group. Survival was significantly better in the P/D group: median survival was 23 months versus 12.8 months, 2-year survival was 49%versus 18.2 %, and 5-year survival was 30.1%versus 9%, respectively (p = 0.004). At multivariate analysis, epithelioid histology, P/D, and completeness of resection were independent prognostic factors. In our experience, P/D, hyperthermic pleural lavage with povidone-iodine, and adjuvant chemotherapy were superior to neoadjuvant chemotherapy, EPP, and adjuvant radiotherapy.